Key facts
- Sense Neuro Diagnostics’s last known valuation is $32.0M (Jan 2026).
- It has raised $32.0M; the latest was Later Stage VC ($9.0M) in Jan 2026.
- Notable investors include Plug and Play Tech Center, US National Science Foundation, Realm Capital Ventures, University of California, Arizona Commerce Authority — 24 tracked in total.
- Status: Privately Held (backing).
- ·The complete investor list — 24 names
- ·Watchlist + deal alerts for Sense Neuro Diagnostics
- ·The full record, as it builds
Funding rounds
No funding rounds for Sense Neuro Diagnostics are on record yet — either the company hasn't raised institutional capital, or the raise hasn't surfaced in our sources.
About Sense Neuro Diagnostics
Developer of AI and machine learning-enabled non-invasive neurodiagnostic medical devices designed to rapidly detect intracranial bleeding and other acute neurological conditions at the point of care. The company offers proprietary RF-based sensing hardware integrated with advanced machine learning algorithms, enabling ambulances, emergency departments, intensive care units, and military medical units to conduct real-time brain assessment without reliance on imaging or specialised infrastructure for faster triage and clinical decision-making.
- Sector
- Healthcare
- HQ
- West Chester, OH, United States
- Founded
- 2013
- Employees
- 11
- Website
- senseneuro.com/
- Ownership
- Privately Held (backing)
Sense Neuro Diagnostics doesn't have a composite mark yet — a PA Mark is published once enough pricing inputs exist (trade prints, fund marks, round prices). The rest of the record below builds toward it.
Recorded secondary trades
No secondary trades in Sense Neuro Diagnostics shares have been recorded yet. When a print lands — third-party, direct report, or platform — it appears here with structure, source, and price.
Institutional fund marks
No SEC-registered fund has reported a fair-value mark on Sense Neuro Diagnostics in its N-PORT filings yet. We sweep new filings monthly.